lipoxin a4 has been researched along with Kidney Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, YP; Jiang, H; Jiang, HK; Li, L; Tian, HY | 1 |
| Ali-Shah, ST; Börgeson, E; Colas, RA; Dalli, J; Godson, C; Guiry, PJ; Johnson, AM; Lee, YS; Serhan, CN; Sharma, K; Syed, GH; Till, A | 1 |
| Börgeson, E; Docherty, NG; Godson, C; Goldschmeding, R; Guiry, PJ; Higgins, DF; Murphy, M; O'Sullivan, TP; Rodgers, K; Ryan, A | 1 |
3 other study(ies) available for lipoxin a4 and Kidney Diseases
| Article | Year |
|---|---|
Lipoxin A4 may attenuate the progression of obesity-related glomerulopathy by inhibiting NF-κB and ERK/p38 MAPK-dependent inflammation.
Topics: Animals; Body Weight; Diet, High-Fat; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; I-kappa B Proteins; Inflammation; Injections, Intraperitoneal; Kidney Diseases; Kidney Glomerulus; Lipoxins; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; NF-kappa B; Obesity; p38 Mitogen-Activated Protein Kinases; Risk Factors | 2018 |
Lipoxin A4 Attenuates Obesity-Induced Adipose Inflammation and Associated Liver and Kidney Disease.
Topics: Adipose Tissue; Animals; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Inflammation; Kidney; Kidney Diseases; Lipoxins; Liver; Liver Diseases; Mice, Inbred C57BL; Obesity | 2015 |
Lipoxin A₄ and benzo-lipoxin A₄ attenuate experimental renal fibrosis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Collagen; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Kidney; Kidney Diseases; Ligation; Lipoxins; Male; Rats; Rats, Wistar; Transforming Growth Factor beta1 | 2011 |